Reduced Risk Alternatives: Exploring Vaping and Heated Tobacco Products

Aug.03.2023
New options such as vaping and heated tobacco offer adult smokers reduced potential health risks compared to traditional cigarettes.

Although the best option is to quit smoking, those who are unable to do so have new options that can help reduce the damage caused to their health by cigarette consumption.

 

In recent years, tobacco companies have embarked on a transformation process, investing in innovation programs, technology, and scientific research to develop products that can offer adult smokers alternatives with reduced potential risk.

 

How they work and how they differ

Among the various options available on the market, vaping, also known as e-cigarettes, and heated or non-combustible tobacco stand out. And although surely all smokers have heard of these alternatives to cigarettes, do they really know about these products? Do they know what they consist of and how they work?

 

On one hand, vaping devices are based on a system that heats a liquid, which may or may not contain nicotine, to generate an inhalable vapor. This system eliminates tobacco combustion and reduces toxic levels by up to 95% compared to conventional cigarettes. The reason? It eliminates the smoke produced by burning traditional cigarettes. Therefore, these products have a potential reduced risk for smokers.

 

Another unique feature is that they eliminate bad odors. Most of the liquids used contain water, propylene glycol, glycerol, and flavors.

 

There are open, closed, and disposable systems. The main difference between the first two is that closed systems already have a pre-established pod, and users can choose from a range of flavors. As for open systems, the user has to manipulate the liquid, which is then filled into the tank, and it can also have different flavors. In the case of disposable devices, everything is integrated into a single unit: mouthpiece, battery, and liquid-heating atomizer.

 

Both vaping and heated tobacco are the result of years of research.

On the other hand, there are heated tobacco or non-combustible tobacco products that use the "heat not burn" technology. These are devices that heat specially designed tobacco units.

 

In this case, the tobacco is only heated to a temperature of up to 400°C without needing to reach high temperatures for burning (there is no combustion). This generates an aerosol that does not contain the solid particles found in cigarette smoke.

 

What do they have in common?

Although both alternatives to cigarettes eliminate tobacco combustion and are classified as options with reduced potential risk, they are not exactly the same products. However, in both cases, there is no combustion, which means there are no ashes or other residues, and they eliminate bad odors.

 

In the case of liquids, most of them contain water, propylene glycol, glycerol, and flavors, so they do not produce the unpleasant smell of traditional cigarettes, and the vapor aroma does not linger on hair or clothes. Similarly, heated tobacco products eliminate cigarette smoke, resulting in fewer persistent odors.

 

But most importantly, both options offer adult smokers alternatives to traditional tobacco consumption that can help, in many cases, to switch from the habit of smoking to the consumption of products with reduced potential risk.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
EU Vape, Heated Tobacco and Nicotine Pouch Tax Reform Reaches Ministerial Talks: Sweden Opposes Proposed 2032 Minimum of 50% of Retail Price or €50/kg for Nicotine Pouches
EU Vape, Heated Tobacco and Nicotine Pouch Tax Reform Reaches Ministerial Talks: Sweden Opposes Proposed 2032 Minimum of 50% of Retail Price or €50/kg for Nicotine Pouches
EU finance ministers are scheduled to discuss tobacco excise reform on November 9, 2026, seeking agreement on higher minimum duties for conventional tobacco and a common EU minimum tax framework covering e-cigarettes, heated tobacco and nicotine pouches. A November 5 Council document identifies nicotine pouch taxation as the main outstanding issue. The Irish Council presidency proposes phased increases, reaching 50% of retail selling price or €50 per kilogram in 2032. Sweden has formally said it cannot support the current compromise, objecting to both the proposed nicotine pouch tax burden and the adjustment of minimum rates based on national purchasing power. The package also addresses cross-border personal-use reference quantities, raw tobacco controls and the continued exclusion of traditional tobacco snus.
Regulations
Nov.10
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
New Australian government estimates released on November 15, 2026, suggest that the country's illicit tobacco market may have contracted for the first time following five years of growth. Estimated market volume fell from a previous peak of 5,972 tonnes to a range of 4,453–5,893 tonnes. The government attributed the change to stronger border enforcement and coordinated domestic operations. Australian Border Force seized more than 2,300 tonnes of illicit tobacco and 13.2 million illicit vaping products in 2025–26, followed by approximately 730 tonnes of illicit tobacco in the first quarter of 2026–27. Separate experimental estimates from the Australian Bureau of Statistics indicate that illicit sources accounted for approximately 80% of nicotine consumption in 2025.
Regulations
Nov.16
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives